[Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].
In Europe, patients who may benefit from an HER2 targeted drug are currently selected by immunohistochemistry (IHC). In situ hybridization (ISH) techniques should be used for complementary assessment of ambiguous 2+ IHC cases and for the calibration of the IHC technique. Eligibility to an HER2 target treatment is defined by an HER2 positive status being IHC test 3+ or 2+ amplified. Reliable detection of HER2 status is essential to the appropriate usage of HER2 targeted drugs because its specificity is limited to tumors overexpressing HER2. It is essential that the IHC evaluation of the HER2 status of a mammary carcinoma is optimized and reliable. This GEFPICS' guidelines look over the different steps of the IHC technique, the controls and, the rules for interpretation. Once acquired, this knowledge must be perpetuated by the observation of rules of good technical practice (internal and external controls, quality assurance programs).
Centre Jean-Perrin, département de pathologie, 58, rue Montalembert, 63011 Clermont-Ferrand, France. fpenault@cjp.fr
Frédérique
F
Penault-Llorca
Anne
A
Vincent-Salomon
Jean-Pierre
JP
Bellocq
Marie-Christine
MC
Matthieu
Gaetan-Mac
GM
Grogan
Isabelle
I
Treilleux
Francette
F
Ettore
Sophie
S
Laberge-Le Couteulx
Brigitte
B
Sigal
Jerome
J
Couturier
Magali
M
Lacroix-Triki
Martine
M
Antoine
André
A
Balaton
Marie-Christine
MC
Baranzelli
Valérie
V
Becette
Cécile
C
Blanc-Fournier
Frédéric
F
Bibeau
Eva
E
Brabencova
Sabrina
S
Croce
Viviana
V
Fridman
Pascal
P
Génin
Jean-Pierre
JP
Ghnassia
Jocelyne
J
Jacquemier
Bruno
B
Poulet
Pascal
P
Roger
Christine
C
Sagan
Patrick
P
Tas
Martine
M
Trassard
Véronique
V
Verriele
Laurent
L
Arnould
D001943:Breast Neoplasms / Q000737:chemistry* / Q000473:pathology*; D005602:France; D006801:Humans; D007150:Immunohistochemistry / Q000592:standards; D017403:In Situ Hybridization / Q000592:standards; D011786:Quality Control; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011996:Records
D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human